Abstract 636P
Background
Advanced androgen signaling inhibition, a prevailing therapy approach in advanced prostate cancer, incurs variable response. Therapy selection guided by predictors is an unmet need.
Methods
We reviewed MDACC GU department and Hellenic Sister Institute records for Abiraterone Acetate (AA) treated mCRPC patients (pts) with extraordinary response (absence of radiographic/clinical progression for ≥3 years). We compared to reported findings for COU-AA-302 and real world experience to identify candidate predictors of outcome. We applied a previously proposed COU-AA-302 response prognostic model. Archived diagnostic and subsequent tumor specimens were retrieved for molecular characterization.
Results
Forty four of 430 reviewed mCRPC pts had extraordinary response. Table depicts features. Median time to AA discontinuation was 5.8 yr (range 3-12.5+) and 20 pts are on treatment. Safety profile is acceptable with no overt increase in fractures or cardiovascular, metabolic morbidity. All pts experienced >50% PSA decline with nadir ≤0.1 in 80%, occurring within 5mo (median) (range <1-57). Median time to PSA progression 5.9 yr (95% CI 4.4-7.5), median rPFS 11.5 yr. Median OS 9.4 yr (95% CI 8.1-10.7). Pretreatment features differed significantly from other datasets for: Longer time from cancer diagnosis (median 8.5 yr), longer time to CRPC (median 3.1 yr), bone metastatic burden (63% ≤3 lesions), and PSA (median 5.5 yr). We applied the model to the cohort and it predicted only 7/44 (16%). Tissue analyses to be reported at meeting due to COVID19 research shutdown. Table: 636P
| n (%)/ median (range) | |
| 44 | |
| Race | |
| White | 37 (84) |
| Black | 7 (16) |
| Diagnostic Gleason ≥8 | 25 (60) |
| Diagnostic PSA | 29.3 (8.4-106) |
| Diagnostic stage | |
| M+ | 10 (23) |
| M0N+ | 5 (12) |
| M0 | 28 (65) |
| Local Tx | |
| Yes | 31 (70) |
| Radical prostatectomy (RP) | 28 (64) |
| EBRT | 22(50) |
| RP + EBRT | 19 (43) |
| Time to LHRH resistance (yr) | 3.1 (0.5-17.5) |
| Systemic Tx – Lines | 2 (1-5) |
| Antiandrogen | 29 (66) |
| Other hormone | 13 (30) |
| Chemo | 9 (20) |
| Immunotherapy | 7 (16) |
| Other | 3 (7) |
| Time from diagnosis to AA | 8.5 (<1-22.1) |
| Time to CRPC | 4.7 (0.6-21.6) |
| ECOG | 0 (0-2) |
| BMI | 29.4 (19-40) |
| Extent of disease | |
| Bone only | 18 (41) |
| Bone | 27 (61) |
| ≥10 mets | 9 (20) |
| <10 | 35 (80) |
| 34 (77) | |
| Node only | 15 (34) |
| Visceral | 4 (9) |
| Bsl PSA | 5.5 (0.1-657) |
| Bsl ALP | 75 (42-369) |
| Bsl LDH | 452 (166-659) |
| Bsl Hgb | 12.8 (12.5-14.1) |
Conclusions
Extraordinary response to enhanced androgen signaling inhibition in mCRPC appears linked to androgen signaling ‘addiction’ and limited disease volume. Available prognostic models are not sensitive enough to guide selection. Routine biopsy derived predictors will help guide therapeutic strategies and improve curative fraction in advanced prostate cancer. Ref: https://doi.org/10.1016/j.clgc.2017.07.014.
Clinical trial identification
MDACC: PA16-0736.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S.K. Subudhi: Advisory/Consultancy: Valeant; Honoraria (self), Advisory/Consultancy: Dendreon; Honoraria (self), Advisory/Consultancy, and Ownership interest: Apricity Health; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Janssen; Honoraria (self), Advisory/Consultancy: Polaris; Advisory/Consultancy: Amgen; Advisory/Consultancy: Bayer; Advisory/Consultancy: Exelixis; Research grant/Funding (institution): Bristol-Myers-Squibb; Research grant/Funding (institution): AstraZeneca; Honoraria (self): Compugen; Honoraria (self): Parker Institute of Cancer Immunotherapy; Honoraria (self): Society for Immunotherapy od Cancer. C. Logothetis: Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Janssen; Research grant/Funding (institution): Bristol-Myers-Squibb; Advisory/Consultancy, Research grant/Funding (institution): Pfizer. E. Efstathiou: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Sanofi; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Janssen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Astellas; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Tolmar; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Oric. All other authors have declared no conflicts of interest.